Ultimovacs declares trial results of UV1 cancer vaccine.

Ultimovacs, a biotechnology company in its clinical stages, has unveiled data from the Phase II NIPU trial on the UV1 cancer vaccine, focusing on mesothelioma. This trial, led by investigators, evaluated the impact of integrating the vaccine into second-line treatment alongside ipilimumab and nivolumab for patients with pleural mesothelioma, a particularly aggressive form of cancer affecting the chest cavity and lungs' lining.

Conducted across six university hospitals in Denmark, Australia, Norway, Spain, and Sweden and backed by Oslo University Hospital, Bristol-Myers Squibb, and Ultimovacs, the trial randomized 118 patients from June 2020 to January 2023. Although the primary goal of enhancing progression-free survival (PFS) was not achieved, secondary endpoints displayed notable benefits. These included improved objective response rate (ORR) and overall survival (OS), especially among patients with the epithelioid subtype of mesothelioma.